Understand how we got here — and how to move forward.



Advance your organization’s biomarker testing program


    Biomarker testing is an essential part of the precision medicine toolbox that clinicians can use to advance care and make targeted treatment decisions. However, approaches to biomarker testing within and across an organization can vary and lead to inefficient processes, differences in quality of care, and unnecessary costs.

    This diagnostic tool is designed to help oncology service line leaders and clinicians understand whether their biomarker testing program is basic, intermediate, or advanced. After using this tool, leaders will be able to identify necessary steps to standardize and improve their organization’s biomarker testing process.

    Sponsored by
    Pfizer logo

    This material is sponsored by Pfizer. Advisory Board experts wrote the material, conducting the underlying research independently and objectively. Pfizer had the opportunity to review the material.


    About the sponsor

    At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.

    Learn More About Pfizer

    This material is sponsored by Pfizer, an Advisory Board member organization. Representatives of Pfizer helped select the topics and issues addressed. Advisory Board experts wrote the material, maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.

    To learn more, view our editorial guidelines

    Have a Question?


    Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.